{
    "url_original": "https://www.wsj.com/articles/merck-to-buy-acceleron-pharma-for-11-5-billion-11633005328?mod=business_lead_pos4",
    "url": "merck-to-buy-acceleron-pharma-for-11-5-billion-11633005328",
    "title": "Merck to Buy Acceleron Pharma for $11.5 Billion",
    "sub_head": "Pharmaceutical giant enhances its rare-disease business with a bet on treatments for respiratory and blood diseases",
    "category_1": "Business",
    "image_1_url": "https://images.wsj.net/im-409273?width=860&height=573",
    "image_1": "im-409273.jpg",
    "time": "2021-09-30 08:35:00",
    "body": "Merck  & Co. has agreed to buy  Acceleron Pharma Inc.  for $11.5 billion, bolstering the pharmaceutical giant’s rare-disease business.<br />The cash deal values Acceleron at $180 a share, the companies said Thursday. The deal is one of Merck’s biggest and represents a bet on treatments for respiratory and blood diseases that Acceleron specializes in."
}